Literature DB >> 16242634

Small non-fibrillar assemblies of amyloid beta-protein bearing the Arctic mutation induce rapid neuritic degeneration.

Brian M Whalen1, Dennis J Selkoe, Dean M Hartley.   

Abstract

Recent studies suggest that soluble intermediates formed during amyloid beta-protein (Abeta) fibrillogenesis are neurotoxic. We studied early aggregation assemblies of wild-type and mutant Abeta bearing the E22G ("Arctic") familial Alzheimer's disease mutation. Using a novel method to present purified, disaggregated Abeta peptides to primary cortical neurons, the detailed temporal pattern of neurotoxicity was assessed. Neurons exposed to Arctic Abeta showed a progressive degeneration that was much more rapid than that with wild-type Abeta, beginning in dendrites and axons and leading to frank cell death. This neurotoxicity paralleled the aggregation process, with neuritic injury first appearing in the presence of small spherical Abeta oligomers, which were followed by a time-dependent elongation of curvilinear Abeta assemblies. One of the earliest neuritic changes was the formation of neurofilament-positive ringlets within axons, which disappeared as neurites followed by cell body degeneration. Our data support the hypothesis that small Abeta intermediates formed early in the aggregation process initiate cellular dysfunction beginning in neurites, leading to neuronal loss. A similar pattern of degeneration may occur during the preclinical and early clinical phases of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16242634     DOI: 10.1016/j.nbd.2005.03.007

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  35 in total

1.  Preparation and characterization of toxic Abeta aggregates for structural and functional studies in Alzheimer's disease research.

Authors:  Asad Jan; Dean M Hartley; Hilal A Lashuel
Journal:  Nat Protoc       Date:  2010-06-03       Impact factor: 13.491

Review 2.  The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease.

Authors:  Sergio T Ferreira; William L Klein
Journal:  Neurobiol Learn Mem       Date:  2011-09-06       Impact factor: 2.877

Review 3.  The case for rejecting the amyloid cascade hypothesis.

Authors:  Karl Herrup
Journal:  Nat Neurosci       Date:  2015-06       Impact factor: 24.884

4.  Effect of pathogenic mutations on the structure and dynamics of Alzheimer's A beta 42-amyloid oligomers.

Authors:  Kristin Kassler; Anselm H C Horn; Heinrich Sticht
Journal:  J Mol Model       Date:  2009-11-12       Impact factor: 1.810

Review 5.  Transgenic Drosophila models of Alzheimer's disease and tauopathies.

Authors:  Kanae Iijima-Ando; Koichi Iijima
Journal:  Brain Struct Funct       Date:  2009-12-05       Impact factor: 3.270

6.  Tauroursodeoxycholic acid prevents E22Q Alzheimer's Abeta toxicity in human cerebral endothelial cells.

Authors:  R J S Viana; A F Nunes; R E Castro; R M Ramalho; J Meyerson; S Fossati; J Ghiso; A Rostagno; C M P Rodrigues
Journal:  Cell Mol Life Sci       Date:  2009-03       Impact factor: 9.261

7.  Sequestration of the Abeta peptide prevents toxicity and promotes degradation in vivo.

Authors:  Leila M Luheshi; Wolfgang Hoyer; Teresa Pereira de Barros; Iris van Dijk Härd; Ann-Christin Brorsson; Bertil Macao; Cecilia Persson; Damian C Crowther; David A Lomas; Stefan Ståhl; Christopher M Dobson; Torleif Härd
Journal:  PLoS Biol       Date:  2010-03-16       Impact factor: 8.029

8.  Alzheimer's disease: synaptic dysfunction and Abeta.

Authors:  Ganesh M Shankar; Dominic M Walsh
Journal:  Mol Neurodegener       Date:  2009-11-23       Impact factor: 14.195

9.  Does neuroinflammation fan the flame in neurodegenerative diseases?

Authors:  Tamy C Frank-Cannon; Laura T Alto; Fiona E McAlpine; Malú G Tansey
Journal:  Mol Neurodegener       Date:  2009-11-16       Impact factor: 14.195

10.  Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575.

Authors:  Monica Garcia-Alloza; Meenakshi Subramanian; Diana Thyssen; Laura A Borrelli; Abdul Fauq; Pritam Das; Todd E Golde; Bradley T Hyman; Brian J Bacskai
Journal:  Mol Neurodegener       Date:  2009-05-06       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.